The IHAT-GUT Iron Supplementation Trial in Rural Gambia: Barriers, Facilitators, and Benefits. by Stelle, Isabella et al.
nutrients
Article
The IHAT-GUT Iron Supplementation Trial in Rural Gambia:
Barriers, Facilitators, and Benefits
Isabella Stelle 1,2,* , Lorraine K. McDonagh 3 , Ilias Hossain 4, Anastasia Z. Kalea 1,5,* and Dora I. A. Pereira 4,6


Citation: Stelle, I.; McDonagh, L.K.;
Hossain, I.; Kalea, A.Z.; Pereira, D.I.A.
The IHAT-GUT Iron Supplementation
Trial in Rural Gambia: Barriers,
Facilitators, and Benefits. Nutrients
2021, 13, 1140. https://doi.org/
10.3390/nu13041140
Academic Editor: James Swain
Received: 18 February 2021
Accepted: 27 March 2021
Published: 30 March 2021
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affil-
iations.
Copyright: © 2021 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
1 Division of Medicine, Institute of Liver and Digestive Health, University College London (UCL),
London WC1E 6BT, UK
2 Women and Children’s Health Department, Division of Medicine, King’s College London (KCL),
London SE1 7EH, UK
3 Research Department of Primary Care and Population Health, University College London (UCL),
London NW3 2PF, UK; l.mcdonagh@ucl.ac.uk
4 Medical Research Council Unit the Gambia at the London School of Hygiene & Tropical Medicine, Banjul,
The Gambia; mihossain@mrc.gm (I.H.); diap2@icloud.com (D.I.A.P.)
5 Institute of Cardiovascular Science, University College London (UCL), London WC1E 6BT, UK
6 Department of Pathology, University of Cambridge, Cambridge CB2 1QP, UK
* Correspondence: isabella.stelle@gmail.com (I.S.); a.kalea@ucl.ac.uk (A.Z.K.)
Abstract: Introduction: In most sub-Saharan African countries iron deficiency anaemia remains
highly prevalent in children and this has not changed in the last 25 years. Supplementation with
iron hydroxide adipate tartrate (IHAT) was being investigated in anaemic children in a phase two
clinical trial (termed IHAT-GUT), conducted at the Medical Research Council Unit the Gambia at the
London School of Hygiene and Tropical Medicine (LSHTM) (abbreviated as MRCG hereof). This
qualitative study aimed to explore the personal perceptions of the trial staff in relation to conducting
a clinical trial in such settings in order to highlight the health system specific needs and strengths
in the rural, resource-poor setting of the Upper River Region in the Gambia. Methods: Individual
interviews (n = 17) were conducted with local trial staff of the IHAT-GUT trial. Data were analysed
using inductive thematic analysis. Results: Potential barriers and facilitators to conducting this
clinical trial were identified at the patient, staff, and trial management levels. Several challenges, such
as the rural location and cultural context, were identified but noted as not being long-term inhibitors.
Participants believed the facilitators and benefits outnumbered the barriers, and included the impact
on education and healthcare, the ambitious and knowledgeable locally recruited staff, and the local
partnership. Conclusions: While facilitators and barriers were identified to conducting this clinical
trial in a rural, resource-poor setting, the overall impact was perceived as beneficial, and this study
is a useful example of community involvement and partnership for further health improvement
programs. To effectively implement a nutrition intervention, the local health systems and context
must be carefully considered through qualitative research beforehand.
Keywords: anaemia; iron deficiency anaemia; iron deficiency; micronutrients; iron; clinical trial;
nutrition intervention; public health; global health; malnutrition; low resource setting; qualitative
1. Introduction
1.1. Iron Deficiency and the IHAT-GUT Trial in the Gambia
Iron deficiency (ID) poses one of the most significant public health burdens today.
At any given moment, more individuals suffer from ID than any other health problem,
with an estimated 1.24 billion affected individuals worldwide [1]. ID is associated with
multiple pathologies, including anaemia and defective organ function [2]. The prevalence
of anaemia is five times higher in low- and middle-income countries (LMICs) than high-
income countries, with ~30% of the world’s population, and 43% of 6–59 months old
children, being anaemic [1,3]. In Sub-Saharan Africa, 79% of children under six years are
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anaemic and iron deficiency anaemia (IDA) affects 58% of pre-school children [4]. As such,
IDA is the largest international nutritional deficiency disorder and one of the five leading
causes of global disease burden [1].
Despite widespread supplementation schemes, ID prevalence has not changed much
in LMICs over the last 25 years [5]. There is growing interest in developing novel nano-
iron compounds or delivery systems for fortification and supplementation [2,6–9]. One
proposed strategy is a targeted-release nano-iron formulation [10]. Iron hydroxide adipate
tartrate (IHAT) and standard-of-care ferrous sulphate were tested in a randomised placebo-
controlled double-blind clinical trial (acronym IHAT-GUT) conducted at the Medical
Research Council Unit the Gambia at the London School of Hygiene and Tropical Medicine
(LSHTM) (abbreviated as MRCG hereof) [11].
1.2. Nutrition Interventions in Varying Contexts and the Need for Qualitative Data
While integrating nutrition-specific interventions into health systems can be impactful
for both health and nutrition outcomes, different countries will have specific delivery needs
for implementation [12]. Until the barriers and facilitators of nutrition intervention trials are
studied across various settings, there will be a lack of data to implement such interventions.
Additionally, LMICs remain underrepresented in research [13]. The Global Forum of
Health Research termed this the “10/90 gap” to exemplify that less than 10% of health
research funds go towards problems affecting 90% of the population worldwide [14], with
a smaller percentage towards LMICs [15,16]. Evidently, clinical research is skewed, with
more than 80% of clinical trials occurring in high-income countries [17–19] and only ~1% of
drugs produced between 1975–2004 addressing LMIC issues [20]. Research enhancement
in LMICs is an efficient and beneficial way to correct this gap [14].
1.3. Clinical Nutrition Trials in LMICs
Given the state of healthcare and disease prevalence in LMICs, clinical trials are well
received, and participant recruitment is often easier than in a health secure country [13,21].
The ethical argument remains that medicines targeting conditions highly prevalent in
LMICs should be tested in those populations, without transferring data from high-income
settings. Interventions often have the largest impact medically in LMICs and benefit from
involving local staff [22–24].
Difficulties of conducting clinical trials in LMICs stem from limitations in obtaining
informed consent, ethical compensation mechanisms, poor health infrastructure, socio-
economic and cultural differences [21], and lack of education amongst study partici-
pants [25,26]. Additional barriers are limited research governance, funding, logistics,
commercial ability, infrastructure, research materials, overall research capacity, and unsup-
portive administrative and government systems [15,16,25,27–30]. A recent review looking
at existing integrated health and nutrition programmes across 45 LMIC settings found that
service delivery and health workforce were well-integrated, but governance, information
systems, finance and supplies, and technology were less well-integrated [12].
The aim of this study was to: qualitatively explore IHAT-GUT trial staff perceptions
of barriers and facilitators to conducting this clinical trial to highlight the health system
specific needs and strengths in a rural and resource-poor setting.
2. Methods
2.1. IHAT-GUT
IHAT-GUT was conducted on children with anaemia between the age of 6 and
35 months, living in The Upper River Region (URR) of the Gambia [11]. The children
were enrolled in the trial for 113 days, within which they underwent supplementation
for 85 days, with weekly study visits to test haemoglobin (Hb) levels and malaria status,
and three study timepoints included venous blood collection. Further information about
IHAT-GUT study protocol is provided in the protocol paper [11].
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2.2. Study Setting
We describe the involvement of research staff in the iron supplementation trial IHAT-
GUT [11], which was under the governance of MRCG (Figure 1). The Gambia is the smallest
and most densely populated country in West Africa, with about 2.28 million inhabitants, of
which roughly one million (48.6%) live below the national poverty line [31]. Islam is the
predominant religion, polygamy is widely practiced, and families live in multigenerational
compounds within villages [31]. The Gambia is subject to bimodal weather conditions
having a “wet” (June to October) and “dry” (November to May) season. The seasonal
rain determines the farming practices at that time of year, lending to extreme variations in
seasonal diets and fluctuating levels of malnutrition [32].
Figure 1. Study catchment area (circled in black) in the Upper River Region (red inset) of the Gambia (circled in red) in West
Africa (main picture).
2.3. Study Participants
Individual interviews were conducted with 17 IHAT-GUT local trial staff (Table 1).
Trial staff were purposively sampled to ensure insights from varying job types. To maintain
anonymity, participants are identified via job title only.
2.4. Data Collection
Data was collected in person by the first author (IS). Participants chose the location
of the interviews to facilitate a more comfortable environment. Locations included the
MRCG in Basse and Fajara and study sites within the URR. A topic guide (available upon
request) was developed and used to facilitate discussions. Interviews, with informed
consent, were audio recorded and later transcribed verbatim. Photographs were taken
during data collection with informed consent. Interviews continued until no additional
insights were gained (i.e., data saturation [33]).
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Table 1. Demographic characteristics of sample.
Demographics n %
Ethnicity (Tribe) if applicable
Gambian (Fula: Mandinka: Wolof: Banbara: Manjago) 12 (6:3:1:1:1) 70













Highest Level of Education
Secondary School 5 29
State Enrolled Nursing School 3 18
Bachelors 1 5
Medicine Degree 3 18
Masters 3 18
Doctorate a 2 12







a = one in progress. b = MRC Unit the Gambia
2.5. Data Analysis
Transcripts were analysed using inductive thematic analysis to explore patterns in
the data [34]. Braun and Clarke’s six phases of thematic analysis were used (Table 2) [34].
The transcripts were read several times (data familiarisation). Notes were made in relation
to significant and/or interesting comments made by interviewees. The transcripts were
coded, and memos written. A code represented a feature of the data that the researcher
found interesting or insightful in relation to the research questions, and the memo was a
summary of the findings [34]. A list of codes was constructed and connections between
them sought to develop provisional themes (repeated patterned responses within data
sets) and sub-themes [34]. When all transcripts were analysed, a final list of themes and
sub-themes was created.
Table 2. Six phases of thematic analysis adapted from Braun and Clarke (2006).
Phase Description
1. Data Familiarization Transcribing, reading, and re-reading data
2. Initial Codes Coding interesting features systematically and collating the data to each code
3. Theme Development Collating codes into potential themes and adding relevant data to each
4. Refining Themes Ensuring themes work with the first (data familiarization) and second (initialcodes) levels of analysis
5. Naming Themes Ongoing refinement, generating clear definitions and names for each theme
6. The Report Final analysis opportunity, extraction of compelling examples
An inductive approach was used whereby data analysis was data driven so that par-
ticipant’s views took precedence over the interviewer’s previous knowledge or beliefs [34].
That said, previous knowledge will, to some extent, influence the research. Therefore, to
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ensure rigour and validate the finding, transcripts were analysed by the second author
(LMD) using the same procedure. Discrepancies were discussed and jointly altered.
2.6. Ethical Considerations
Ethical approval was obtained from the Gambia Government/MRC Joint Ethics
Committee (REF: L2018.25) in June 2016. The study was conducted in accordance with
the Declaration of Helsinki. Written and verbal informed consent for interviews and
photographs was obtained from each participant. It was made clear that refusal to be
involved would be confidential and would not affect their work; no participants refused to
be interviewed.
3. Results
A distinction was made between barriers and facilitators at three levels: study partici-
pant, trial staff, and trial management.
3.1. Barriers
The barriers included community factors and low incentivisation (participant level),
motivation (staff level), and country context (trial management level) (Figure 2). Illustrative
quotes from each sub-theme of the barriers can be found in Table 3.
Figure 2. Graphical illustration of themes and sub-themes of the barriers.
Table 3. Illustrative quotes for each sub-theme of the barriers.
Theme Sub-Theme Illustrative Quote
Participants Community Factors
“There’s also a bit of cultural problem . . . because in Africa we believe the wife stays
home to cook, clean. So, some husbands decide (to) have their wives stop going to the
clinic visits.”—Data Manager
Low Incentivisation “We take blood from these children, so we need to make life easy for them. Maybe theyare on the drug that doesn’t do anything.”—State Enrolled Nurse 2
Staff Motivation
“There will always be challenges. That you should expect. The biggest challenge is
working with individuals and managing individuals. Everyone has negative qualities,
I have them.”—Research Clinician
Trial
Management Country Context
“The major challenges in running these trials here is the start up. Making all the
necessary arrangements. The necessary approvals from the Ministry, from the
Medicine Control Agency, from the Ethics and SCC (Scientific Coordinating
Committee), establishing the sites of the studies and so forth. And of course, it requires
a lot of logistical support . . . especially if they are in remote areas. IHAT-GUT is
running its study where no study has been done in the past at this scale . . . (and)
during rainy season you have floods.”—Project Manager
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3.1.1. Participants
Community Factors
Many viewed specific cultural factors as barriers to successful running of this trials,
specifically community hierarchies and education. These issues posed challenges with
community sensitisation for the staff, but it was noted that these barriers were easily
overcome if approached properly. Regarding hierarchies, the Local principal investigator
(PI) noted that to run the trial fluidly it was key to “pass the messages [to the communities]
smoothly, so everyone can understand. If your communities understand you won’t have problems
. . . with sensitisation go through the hierarchy: the village level, then compound level, then houses,
then individuals”. Another community norm is that mothers often stay home and mind
the children and household, but during IHAT-GUT, mothers and children had to attend
clinic once a week. The Data Manager stated: “There’s also a bit of cultural problem . . . because
in Africa we believe the wife stays home to cook, clean. So, some husbands decide (to) have their
wives stop going to the clinic visits”. The issue of husbands not wanting their wives to leave
home to attend clinic visits was a barrier to participant recruitment, but with appropriate
informed consent and village hierarchical involvement, this was overcome.
Community education levels were believed to impact the communication of trial
information. While many men attend secondary school, women often leave school during
puberty to start a family. The low level of education was viewed as a barrier to informing
communities about the trial: “The level of awareness, literacy and education here is a challenge
because you want to be sure that the people you are conducting research on are aware of what
your study is about and what the implications are” (Research Clinician). Another barrier was
the misunderstanding about blood sampling. State Enrolled Nurse 1 pointed out that
some parents were reluctant for their child to join the trial (and others withdrew) when
they learnt blood drawing was involved (Figure 3). This was linked to lack of education
and local attitudes towards confusion around clinical research: “Sometimes the awareness
is an issue, some people have the wrong sentiment with the local mindset” (Data Manager). To
overcome this barrier, IHAT-GUT used village sensitisation to inform all villagers about
the trial and of what it consisted.
Figure 3. Photograph of blood drawing during a visit to the study clinic.
Low Incentivisation
State Enrolled Nurse 2 maintained that offering free medication and healthcare was
an incentive to take part in the trial but moving forward researchers in other clinical trials
need to consider incentives beyond the child’s healthcare: “When we do the venous bleeding,
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we give them (the mothers) 50 Dalasis (to buy breakfast), but I would love for it to be more than
that. We take blood from these children, so we need to make life easy for them. Maybe they are on the




As summarised by the Research Clinician, there is always challenges when working
within teams: “There will always be challenges. That you should expect. The biggest challenge
is working with individuals and managing individuals. Everyone has negative qualities, I have
them”. Workload was also noted as a barrier by both the laboratory and data teams, as those
departments “tend to be oversubscribed” (Statistician). The Analytical Project Manager
commented that the workload became unmanageable for the laboratory staff at some points.
Staff motivation was difficult for those with managerial responsibilities (See Supplementary
Figure S1): “Although this is not the first time, I’ve manned a group like this, it’s not easy”
(Field Coordinator; managed thirty employees).
3.1.3. Trial Management
Country Context
The remote setting and harsh weather conditions required extensive planning and
coordination: “Resources are always a problem in developing countries” (Statistician). Likewise,
“IHAT-GUT is running its study where no study has been done in the past at this scale . . . during
rainy season you have floods” (Nutrition Theme Administrator). The Research Clinician
mentioned that: “The weather . . . it’s harsh, it’s quite hot, dusty, you get flooding”. It was also
mentioned that: “You need to consider the environment and circumstance (they) are in a very
robust area in the North Banks” (Local PI) where “the villages are far, and the roads are poor”
(Senior Field Worker). For example, “let’s say you’re living in a place like Kuwonkuba, they
might not have electricity or clean water. This adds stress” (State Enrolled Nurse 1).
The Nutrition Theme Administrator noted that the context made sticking to the tight
project timelines challenging: “The major challenges in running these trials here is . . . making
all the necessary arrangements: approvals from the Ministry, Medicine Control Agency, Ethics
and SCC (Scientific Coordinating Committee), establishing the sites of the studies. And of course,
it requires a lot of logistical support in remote areas”. He also noted handling the “financial
management” of various projects at MRCG in relation to context: “Always expect a project
to overrun, so you adequately allocate expenditures. For example, in clinical trials, you always
have SAEs (Serious Adverse Events)”. The associated expenditures due to the context also
posed a challenge for the Field Coordinator: “It’s a problem . . . we are spending too much on
the (ferry) crossing”. Likewise, transporting mothers from villages to clinics and transferring
samples to the main laboratory facilities added financial stress. The Senior Field Worker
noted funding needs such as giving “(phone) credit to call for the Field Workers and mothers”
so they could afford to make trial related calls.
3.2. Facilitators & Benefits
The facilitators included healthcare, incentivisation, and receptive communities (par-
ticipant level); staff characteristics and education enhancement (staff level); and the local
partnership (trial management level) (Figure 4). Illustrative quotes from each sub-theme of
the facilitators can be found in Table 4.
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Figure 4. Graphical illustration of themes and sub-themes of the facilitators.
Table 4. Illustrative quotes for each sub-theme of the facilitators.
Theme Sub-Theme Illustrative Quote
Participants Health Care
“IHAT-GUT . . . helps the Gambian children and it’s the first one in the
North Bank . . . We are working where they need it most . . . There was more
anaemia, they had less hospitals. Medical care is lacking. Mothers say:
‘please come to our communities’.”—Senior Field Worker
Incentivisation
“You need to bring a social impact, so the participants feel valued (rather)
than just coming to do what you want and not giving the mothers and
children something.”—Data Manager
Receptive Communities
“The Gambians, they are remarkable people. They are the most amazing,
welcoming people. It’s a very friendly environment to work in. It’s a
research-friendly country.”—Research Clinician
Staff Staff Characteristics
“In Europe, I don’t think it would be easy to conduct studies like this. In
Africa, people don’t find it a problem that projects come in their
communities. We are Gambian. When we go into our own communities,
they are accepting.”—Senior Field Worker
Education Enhancement
“The Nutritional Course was great. It added value because it not only
taught us about nutrition personally, but on the other hand, it’s great to do a
team activity. It makes everyone feel appreciated . . . You want to develop the
staff.”—Data Manager
Trial Management Local Partnership
“MRC has a great track record here in the Gambia, they have cordial
relationships with the communities and with The Gambian government and
its ministries.”—Nutrition Theme Administrator
3.2.1. Participants
Healthcare
The study was conducted in the North Bank of the URR where the poorest Gambian
communities reside and the double burden of malnutrition and infection is highest [35].
Scientific Officer 2 noted: “It’s better to give nutritional interventions where they are most
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needed”. This was echoed by the Senior Field Worker: “Especially IHAT-GUT because it helps
the Gambian children and it’s the first one in the North Bank . . . We are working where they need
it most...There was more anaemia, they had less hospitals. Medical care is lacking. Mothers say:
‘please come to our communities’”.
Another advantage for trial participants was that healthcare was fully covered during
the trial. The Nurse Coordinator found that local communities embraced these interven-
tions: “These studies excite them. They want them to continue. We deal with the health, the
management, the transportation.”
Incentivisation
The Data Manager mentioned that: “You need to bring a social impact, so the participants
feel valued (rather) than just coming to do what you want and not giving the mothers and children
something”. A successful incentive was the provision of Yandi juice, which made supple-
ment administration easier and more enjoyable for participants: “Giving the Yandi attracts
the children because they want to take the drugs. When they see the Field Workers, they get excited”
(State Enrolled Nurse 2). The Nurse Coordinator also mentioned how “sometimes the kids
are running for the Fields Workers because they are excited for the juice” and advised to use this
approach in the future.
Receptive Communities
Staff found the communities were receptive towards the study. The Research Clinician,
who is not Gambian himself, found: “The Gambians, they are remarkable people. They are
the most amazing, welcoming people. It’s a very friendly environment to work in. It’s a research-
friendly country”. State Enrolled Nurse 2 highlighted that URR, being a low resource setting,
facilitated this: “The advantage of the project being run here is due to low-income earners, so
having these projects is a big deal . . . They are very cooperative. In an urban area it would have
been harder, but in a rural area they are excited”. The Data Manager echoed this sentiment and
believed a similar trial in the UK would be more challenging.
3.2.2. Staff
Staff Characteristics
It was very helpful that the staff going into the communities to conduct research were
from a similar cultural background and could speak local languages. The Senior Field
Worker highlighted: “In Europe, I don’t think it would be easy to conduct studies like this. In
Africa, people don’t find it a problem that projects come in their communities. We are Gambian.
When we go into our own communities, they are accepting”.
The staff had strong experience and knowledge in working with research studies
in rural Gambia. The Local Safety Monitor was confident that being part of this project
meant having a high calibre of staff with education, knowledge, and experience: “The
teams, the doctors, the researchers, the nurses and so on that we have here are second to no other
country, so you know they can get good work here”. The Analytical Project Manager had the
same confidence in his colleagues: “It’s also that they have people on ground who already have
experience of running these clinical trials, both from the clinical aspects to the field staff. The people
are experienced and consistent ( . . . ) they have had proper training about interacting with the
community and attaining data from them”.
Staff were highly ambitious for themselves and the development of their country. The
Local Safety Monitor mentioned impacting West Africa through public health: “(It’s) very
important to me because it drives you to continue your work, you see the issues and the results and
it’s inspiring to keep doing this work”. Having grown up in the Gambia, the Data Manager
was proud to impact his country: “Growing up here, I’ve always seen malnutrition and poverty,
so I’m conscious of my country’s state ( . . . ) you are contributing to change young people’s lives,
which is just amazing”. Likewise, the Senior Field Worker found: “ . . . I can contribute my
part to help Gambian children”.
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Education Enhancement
The staff felt valued by MRCG and IHAT-GUT, thanks to the knowledge that they
gained and this enriched their work experience and dedication to the trials (See Supplemen-
tary Figure S2). The Field Worker was proud of his personal learning and was grateful for
the educational opportunities: “One thing I like in IHAT-GUT is the blood experience because
it’s a learning experience”. One of The Statistician’s favourite parts of working with MRCG
was their advancement of staff knowledge through training. Likewise, Scientific Officer 2
was able to complete her master’s because of MRCG.
3.2.3. Trial Management
Local Partnership
MRCG’s research unit has been in the Gambia for 70 years, giving them respect in the
country for their long-standing establishment, advances in healthcare, and facilities for epi-
demiological studies and clinical trials. MRCG’s upstanding reputation with The Gambian
Government and communities allowed easier collaboration and authorisation from the
government: “MRC has a great track record here in the Gambia, they have cordial relationships
with the communities and with The Gambian government and its ministries” (Nutrition Theme
Administrator). The Field Coordinator noted that MRCG has an international research
reputation: “They have a high regard in terms of quality research, and they have been in existence
for almost 70 years” (See Supplementary Figure S3). The Analytical Project Manager was
grateful for the high-quality facilities, which allowed the project to run smoothly (Figure 5).
Figure 5. Photograph of sample processing done to Good Clinical Lab Practice standards.
4. Discussion
Clinical research in a LMIC, such as the Gambia, poses challenges. Barriers emerged
in this study, such as mistrust regarding blood drawing. O’Neill et al. [26] looked at the
misconceptions around blood and its impacts on trial participation in a village in rural
Gambia. Originally, participant recruitment for finger-pricking for posed no problem, but
as soon as rumours about the use of the blood and concerns around the health implications
of blood loss started spreading, only 42% of the inhabitants consented [26]. They concluded
that to overcome this barrier one must better inform and educate the villagers [26]. Likewise,
as noted in the literature and concurrent with our findings, in order to facilitate clinical
trials, health education is crucial to avoid misconceptions about diseases in the Gambia [25].
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While LMICs were noted as lacking commercial ability, infrastructure, materials, and
overall research capacity, elsewhere, this was not seen in the present study [15,16,27]. Running
clinical trials through MRCG appeared as a facilitator, while unsupportive administrative
systems were reported to be a barrier for clinical trials in LMICs [27,28]. In terms of “human
capacity,” a recurrent theme in this data was the experienced MRCG staff and investment
in training. In contrast, Ross et al. [33] found that in developed countries, such as the
United States, United Kingdom, Europe, and Australia, lack of staff and adequate training
posed barriers. Likewise, in our study staff motivation was noted as occasionally posing a
barrier, which is concurrent with the literature [27,36].
Materials can be difficult to resource in LMICs and for projects to run smoothly;
advanced planning is needed. However, a lack of resources in LMICs increases the need for
sound research to prioritise these limitations [37]. This barrier of planning and preparation
not only encompasses the materials needed, but also appropriate government approvals,
which was previously noted [27,36]. MRCG’s long-standing establishment and good
government relations ease this potential barrier due to expediated government and ethical
approvals as well as familiarity with product procurement in a resource-limited setting.
Overall, the participants showed a clear awareness of the country contexts’ barriers and
facilitators, and the implications these have for the trial. Going forward, building research
capacity by conducting more clinical trials in LMICs is vital to ease the burden of what are
already rigorous and time-consuming study preparation phases, only complicated by the
resource limitations of LMICs.
The overall impact for the country’s healthcare can be beneficial and outweighs the
barriers described. Our findings are in line with previous research, noting the need for
research in such communities [13,21]. Clinical interventions in LMICs have the largest
impact in decreasing childhood mortality rates [13,21]. The high infection burden setting
of rural Gambia was the ideal setting for IHAT-GUT. If the drug were to be tested in a
high-income, low-infection burden country, its effects might not be translatable to the
country of target, as seen in other clinical trials [38,39].
The ease in recruiting patients was noted as a facilitator in running clinical trials in
LMICs like the Gambia. LMICs offer an attractive setting for clinical trials as there is often
less access to healthcare, so the prospect of healthcare through a clinical trial lends to
shorter periods of participant recruitment [21]. Recruitment time can be five to ten times
quicker in LMICs than in developed regions such as the United States or Europe [30]. For
example, one participant highlighted that he did not think mothers in developed countries
would be happy to enrol their child in a study, but in the Gambia the mothers are willing.
Ross et al. [33] similarly reported in his systematic review of 78 randomized control trials
across the United States, United Kingdom, Europe, and Australia that recruitment for
clinical trials was a challenge. Overall, the staff’s observations about the trial setting being
a facilitator for participant incentivisation and ease of recruitment due to increased access
to healthcare is in agreement with previous literature.
Thanks to the local partnership and strong establishment of MRCG in the Gambia,
the country is well equipped for incoming projects due to receptive communities, ambi-
tious and knowledgeable locally recruited staff, and the research facilities and governance
offered by MRCG. Locally recruited staff working in their own communities made com-
munities receptive to the trial due to increased trust. It was previously reported that
it was beneficial for clinical trials to utilise their local workforce because it allowed for
the use of local knowledge [22]. This made the trials more responsive to the country’s
needs and more effective in influencing policy [24]. Likewise, the staff were aware that
passing knowledge through the family hierarchies may facilitate participant recruitment.
Preliminary community sensitisation that allowed information to be passed through the
appropriate village hierarchy in the Gambia has been successful in the past [23].
Another highlighted facilitator in the trial, beyond just participant healthcare, was par-
ticipant transportation to and from the clinic where the interventions took place. Mobility
has been seen as a barrier for non-participation in a clinical trial in the Gambia [25,29].
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5. Limitations
A few limitations of this study warrant noting. Data was collected by a young white
woman interviewing mostly older men. Broom et al. [40] found heightened “professional-
ism” and self-credentialing by men when interviewed by a woman. Likewise, it has been
noted that gender in research warrants more attention, especially in the context of women
interviewing men, such as men’s assertions of gender identities and gender hierarchy [41].
Additionally, the PI (IS) worked closely with the PI of IHAT-GUT (DIAP) and an associa-
tion of the two women being colleagues may have influenced participant answers due to
concern around socially desirable responding in high-stakes situations where participants
aim to make a good impression [42]. Lastly, IHAT-GUT was noted to be well run, using
different monitoring, training and consenting systems that have not been used by a study
in those communities before. Therefore, facilitators may have been more prominent [27],
making it harder to relate to other clinical trials.
6. Conclusions
This study highlighted the barriers and facilitators to conducting this clinical trial in a
rural and resource-poor setting. It brought to light that for clinical trials to be successful in
such settings, cultural context must be carefully considered. Specifically, researchers should
devote substantial time to engaging with the community to gain insight into pre-existing
beliefs, knowledge, and awareness levels of the population, as well as the social structures
at play.
This study reported that the staff were proud of their high calibre of work and am-
bitious to continue making an impact on the country’s education and healthcare levels.
While barriers were faced in running a clinical trial in this rural, resource-poor setting, the
overall impact was perceived as beneficial, and this study is a useful example of community
involvement and partnership for further health improvement programs. These findings
highlight the value that staff find clinical trials add to their lives as well as the need for
creating and nurturing local partnerships, which enables the continuous embrace and
success of clinical research.
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